Newsletter

Subscribe and recieve updates on this company.

Text STOCKS to 72727 for mobile alerts

We are excited to present Soligenix, Inc. (OTC: SNGX).

Full DD Report for SNGX

You must become a subscriber to view this report.


Recent News from (OTC: SNGX)

Your Daily Scoop: Recro Proceeds, MannKind Zooms, Aduro's Publication
News in focus: REPH, MNKD Recro Pharma plans to resubmit NDA Discussion : On September 4, Recro Pharma ( REPH ) reported positive outcome of its meeting with the FDA regarding its NDA for IV meloxicam that was rejected in last May. Based on the discussion with the FDA, the comp...
Source: SeekingAlpha
Date: September, 07 2018 16:31
Soligenix to Present at BioCentury's 25th Annual NewsMakers in the Biotech Industry
PRINCETON, N.J. , Sept. 5, 2018 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that its Chief ...
Source: PR Newswire
Date: September, 05 2018 06:00
Soligenix Announces Publication of Positive Long-Term Data Supporting Thermostability and Conformational Integrity of the RiVax® Ricin Toxin Vaccine
PRINCETON, N.J. , Sept. 4, 2018 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today publicatio...
Source: PR Newswire
Date: September, 04 2018 06:00
Key events next week - healthcare
Noteworthy events for the week of September 2 - 8 for healthcare investors. More news on: BioLife Solutions, Inc., Endocyte, Inc., Soligenix, Inc., Healthcare stocks news, , Read more ...
Source: SeekingAlpha
Date: August, 31 2018 08:15
Soligenix to Present at the 2018 ESCMID/ASM Conference on Drug Development to Meet the Challenge of Antimicrobial Resistance
PRINCETON, N.J. , Aug. 29, 2018 /PRNewswire/  -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that Dr....
Source: PR Newswire
Date: August, 29 2018 06:00
Midday Gainers / Losers (08/22/2018)
Gainers: YECO +56% . NEWA +30% . EXAS +26% . MYND +22% . PSTG +17% . AGEN +14% . LZB +12% . ADMP +12% . MYGN +11% . EPE +11% . More news on: Yulong Eco-Materials, Newater Technology, Inc., EXACT Sciences Corporation, Stocks on the move, , Read more ... ...
Source: SeekingAlpha
Date: August, 22 2018 12:45
Soligenix receives US patent for improved production of synthetic hypericin
Soligenix (NASDAQ: SNGX ) announces that the US Patent Office has granted the patent titled "Systems and Methods for Producing Synthetic Hypericin". More news on: Soligenix, Inc., Healthcare stocks news, Stocks on the move, Read more ...
Source: SeekingAlpha
Date: August, 22 2018 08:00
Soligenix Receives US Patent for Improved Production of Synthetic Hypericin
PRINCETON, N.J. , Aug. 22, 2018 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that the ...
Source: PR Newswire
Date: August, 22 2018 06:00
SHAREHOLDER ALERT: Purcell Julie & Lefkowitz LLP Is Investigating Soligenix, Inc. for Potential Breaches Of Fiduciary Duty By Its Board of Directors
NEW YORK , Aug. 13, 2018 /PRNewswire/ -- Purcell Julie & Lefkowitz LLP, a class action law firm dedicated to representing shareholders nationwide, is investigating a potential breach of fiduciary duty claim involving the board of directors of Soligenix, Inc. (NASDAQ: SNGX). If...
Source: PR Newswire
Date: August, 13 2018 08:01
Soligenix Announces Recent Accomplishments And Second Quarter 2018 Financial Results
PRINCETON, N.J. , Aug. 8, 2018 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today its recent ...
Source: PR Newswire
Date: August, 08 2018 06:00

 


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-12-140.97010.941.000.9457,455
2018-12-130.970.970.990.9731,921
2018-12-120.981.001.020.96632,833
2018-12-111.030.9921.030.9830,012
2018-12-101.001.031.030.9845,625

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator
2016-12-123893,73810.4066Cover
2016-12-098,94934,21826.1529Cover
2016-12-0813,47326,54750.7515Short
2016-12-0787610,1118.6638Cover
2016-12-051,37529,8124.6122Cover

* Cover Mode

Short Analysis provided by Squeeze Report. Get a complete short report on SNGX.


About Soligenix, Inc. (OTC: SNGX)

Logo for Soligenix, Inc. (OTC: SNGX)

We are a late stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need. We maintain two active business segments: BioTherapeutics and Vaccines/BioDefense. Our BioTherapeutics business segment is developing a first in class photo dynamic therapy SGX utilizing safe, visible light for the treatment of cutaneous T cell lymphoma CTCL , proprietary formulations of oral beclomethasone , dipropionate BDP for the prevention/treatment of gastrointestinal GI disorders characterized by severe inflammation, including pediatric Crohn s disease SGX and acute radiation enteritis SGX , and our novel innate defense regulator IDR technology SGX for the treatment of oral mucositis in head and neck cancer. Our Vaccines/BioDefense business segment includes active development programs for RiVax, our ricin toxin vaccine candidate, VeloThrax, our anthrax vaccine candidate, OrbeShield, our GI acute radiation syndrome GI ARS therapeutic candidate and SGX , our melioidosis therapeutic candidate. The development of our vaccine programs is supported by our heat stabilization technology, known as ThermoVax, under existing and on going government contract funding. With the recently awarded government contract from the National Institute of Allergy and Infectious Diseases NIAID , we will attempt to advance the development of RiVax to protect against exposure to ricin toxin. We plan to use the funds received under our government contracts with the Biomedical Advanced Research and Development Authority BARDA and NIAID to advance the development of OrbeShield for the treatment of GI ARS. Soligenix is a late stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need. Our BioTherapeutics business segment is developing SGX as a novel photodynamic therapy utilizing safe visible light for the treatment of cutaneous T cell lymphoma, our first in class innate defense regulator IDR technology, dusquetide SGX for the treatment of oral mucositis in head and neck cancer, and proprietary formulations of oral beclomethasone , dipropionate BDP for the prevention/treatment of gastrointestinal GI disorders characterized by severe inflammation including pediatric Crohn s disease SGX and acute radiation enteritis SGX . Our Vaccines/BioDefense business segment includes active development programs for RiVax, our ricin toxin vaccine candidate, OrbeShield, our GI acute radiation syndrome therapeutic candidate and SGX , our melioidosis therapeutic candidate. The development of our vaccine programs incorporates the use of our proprietary heat stabilization platform technology, known as ThermoVax. Currently, this business segment is supported with up to million in government grant and contract funding from the National Institute of Allergy and Infectious Diseases NIAID and the Biomedical Advanced Research and Development Authority BARDA .

 

 

 

Current Management

  • Christopher J. Schaber / President, CEO
    • Christopher J. Schaber has over years of experience in the pharmaceutical and biotechnology industry. Dr. Schaber has been our President and Chief Executive Officer and a director since August . He was appointed Chairman of the Board in October . He also serves on the board of directors of the Biotechnology Council of New Jersey since and the Alliance for Biosecurity since , and has been a member of the corporate councils of both the National Organization for Rare Diseases and the American Society for Blood and Marrow Transplantation since . Dr. Schaber served from to as Executive VP and Chief Operating Officer of Discovery Laboratories, Inc., where he was responsible for overall pipeline development and key areas of commercial operations, including regulatory affairs, quality control and assurance, manufacturing and distribution, preclinical and clinical research, and medical affairs, as well as coordination of commercial launch preparation activities. From to , Dr. Schaber was a cofounder of Acute Therapeutics, Inc., and served as its VP of Regulatory Compliance and Drug Development. From to , Dr. Schaber was employed by Ohmeda PPD, Inc., as Worldwide Director of Regulatory Affairs and Operations. Dr. Schaber received his BA degree from Western Maryland College, his MS degree in Pharmaceutics from Temple University School of Pharmacy and his PhD degree in Pharmaceutical Sciences from the Union Graduate School.
  • Karen Krumeich / CFO
    • Ms. Krumeich has served as Chief Financial Officer and VP of Finance for public and private emerginggrowth, startup and national companies in various sectors of healthcare, including pharmaceuticals, medical devices and healthcare service companies. She has expertise in equity financings, both private and public, Sarbanes compliance, acquisitions and integrations, strategic business development and operations analysis. Most recently Ms. Krumeich was the VP of Finance for Cerecor Inc., a clinical stage neuroscience company. Prior to joining Cerecor she was a CFO Partner with Tatum, a national consulting firm, and a member of the firm s National Healthcare Group. As a Partner with Tatum, she served as Interim Chief Financial Officer for drug development and medical device companies. Prior to joining Tatum in , she was the VP of Finance and Chief Financial Officer of Mela Sciences, Inc. a developmentstage medical device company. At Mela Sciences, she played a key role in the company s initial public offering and was responsible for all functional areas of finance and accounting, administration, and investor relations. As VP of Finance of GranCare Pharmacies, she was responsible for the financial leadership of the pharmacy division and directed an aggressive acquisition program. Ms. Krumeich began her career with a B.S. in Pharmacy from the University of Toledo, subsequently completed an accounting major and transitioned into finance after completing the CPA exam.
  • Richard Straube / Senior VP, Chief Med. Officer
    • Richard C. Straube has over years experience in both academia and industry, he is a boardcertified pediatrician with clinical research experience in hostresponse modulation, most notably with Centocor, Ohmeda Pharmaceuticals, INO Therapeutics, and Stealth Peptides, Inc. While with Centocor, Dr. Straube was responsible for the initial anticytokine and antiendotoxin programs targeted at ameliorating inappropriate host responses to infectious and immunologic challenges. Programs that he has managed include assessments of immunomodulation using monoclonal removal of inciting molecular triggers, removal of internal immunemessengers, augmentation of normal host defenses, and maintenance of normal subcellular function in the face of injury. He was also the founding Chief Medical Officer for INO Therapeutics and was responsible for the clinical trials and subsequent approval of inhaled nitric oxide for the treatment of persistent pulmonary hypertension in the newborn. Dr. Straube received his medical degree and residency training at the University of Chicago, completed a joint adult and pediatrician infectious diseases fellowship at the University of California, San Diego UCSD , and as a Milbank Scholar completed training in clinical trial design at the London School of Hygiene and Tropical Medicine. While on the faculty at the UCSD Medical Center, his research focused on interventional studies for serious viral infections.
  • Oreola Donini / Senior VP, Chief Scientific Officer
    • Oreola Donini, PhD, has served as the Vice President of Preclinical Research and Development of the Company since August , . She has more than years experience in drug discovery and preclinical development with startup biotechnology companies. From to , Dr. Donini worked with ESSA Pharma Inc. as Vice President Research and Development. From to , Dr. Donini worked with Inimex Pharmaceuticals Inc.Lastly as Senior Director of Preclinical R amp D from . Prior to joining Inimex, she worked with Kinetek Pharmaceuticals Inc., developing therapies for infectious disease, cancer and cancer supportive care. Dr. Donini is a coinventor and leader of the SGX innate defense regulator technology, developed by Inimex and subsequently acquired by the Company. She was responsible for overseeing the manufacturing and preclinical testing of SGX , which demonstrated efficacy in combating bacterial infections and mitigating the effects of tissue damage due to trauma, infection, radiation and/or chemotherapy treatment. These preclinical studies resulted in a successful Phase clinical study and clearance of Phase protocols for oral mucositis in head and neck cancer and acute bacterial skin and skin structure infections. While with ESSA Pharma Inc. as the Vice President of Research and Development, Dr. Donini led the preclinical testing of a novel Nterminal domain inhibitor of the androgen receptor for the treatment of prostate cancer. While with Kinetek Pharmaceuticals Inc., her work related to the discovery of novel kinase and phosphatase inhibitors for the treatment of cancer. Dr. Donini received her Ph.D. from Queen s University in Kinston, Ontario, Canada and completed her postdoctoral work at the University of California, San Francisco. Her research has spanned drug discovery, preclinical development, manufacturing and clinical development in infectious disease, cancer and cancer supportive care.
  • Christopher J. Schaber / Chairman
    • Christopher J. Schaber has over years of experience in the pharmaceutical and biotechnology industry. Dr. Schaber has been our President and Chief Executive Officer and a director since August . He was appointed Chairman of the Board in October . He also serves on the board of directors of the Biotechnology Council of New Jersey since and the Alliance for Biosecurity since , and has been a member of the corporate councils of both the National Organization for Rare Diseases and the American Society for Blood and Marrow Transplantation since . Dr. Schaber served from to as Executive VP and Chief Operating Officer of Discovery Laboratories, Inc., where he was responsible for overall pipeline development and key areas of commercial operations, including regulatory affairs, quality control and assurance, manufacturing and distribution, preclinical and clinical research, and medical affairs, as well as coordination of commercial launch preparation activities. From to , Dr. Schaber was a cofounder of Acute Therapeutics, Inc., and served as its VP of Regulatory Compliance and Drug Development. From to , Dr. Schaber was employed by Ohmeda PPD, Inc., as Worldwide Director of Regulatory Affairs and Operations. Dr. Schaber received his BA degree from Western Maryland College, his MS degree in Pharmaceutics from Temple University School of Pharmacy and his PhD degree in Pharmaceutical Sciences from the Union Graduate School.
  • Keith Brownlie / Director
    • Keith Brownlie has been a director since June , . Mr. Brownlie currently serves as a member of the Board of Directors of Epicept Corporation, a publicly traded, specialty pharmaceutical company focused on the clinical development and commercialization of pharmaceutical products for the treatment of cancer and pain, a position he has held since April . From to , Mr. Brownlie worked with the accounting firm of Ernst amp Young LLP where he served as audit partner for numerous public companies and was the Life Sciences Industry Leader for the New York metro area where he was involved with over public and private financings and M amp A transactions. Mr. Brownlie received a BS in Accounting from Lehigh University and is a Certified Public Accountant in the state of New Jersey. Mr. Brownlie cofounded the New Jersey Entrepreneur of the Year Program and was Vice President and Trustee of the New Jersey Society of CPAs. In addition, he served as accounting advisor to the board of the Biotechnology Council of New Jersey.
  • Marco Brughera / Director
    • Marco Brughera has been a director since October . He is the Global Head of the SigmaTau Rare Disease Business Unit., a position he has held since October . Currently he is also President of SigmaTau Pharmaceuticals Inc., President of SigmaTau Research Switzerland S.A. and Chief Executive Officer of SigmaTau Pharma Ltd. From January through October , Dr. Brughera held several other positions with the SigmaTau Group, including Corporate Research and Development Managing Director of SigmaTau Industrie Farmaceutiche Riunite S.p.A. From December through January , Dr. Brughera served on the Board of Directors of Gentium S.p.A., a publicly traded biopharmaceutical company. From to , Dr. Brughera served as the Vice President of Preclinical Development at Nerviano Medical Sciences S.r.l. NMS Group , a pharmaceutical oncologyfocused integrated discovery and development company. He also served as the Managing Director at Accelera S.r.l., an independent contract research organization affiliated with the NMS Group. From to , Dr. Brughera held several senior level positions in the areas of discovery and development with Pharmacia Corporation and Pfizer, Inc. Prior to , he held various positions at Pharmacia amp Upjohn Company, Inc. and Farmitalia Carlo Erba S.p.A., an Italian pharmaceutical company. Dr. Brughera earned his degree in veterinary medicine from the University of Milan and is a European Registered Toxicologist.
  • Gregg Lapointe / Director
    • Gregg Lapointe, CPA, MBA has been a director since March . Mr. Lapointe is currently CEO of Cerium Pharmaceuticals, Inc. and serves on the Board of Directors of SciClone Pharmaceuticals, Inc., Cambrooke Therapeutics, Inc., Raptor Pharmaceuticals, Inc., and the Board of Trustees of the Keck Graduate Institute of Applied Life Sciences. He has previously served on the Board of Directors of the Pharmaceuticals Research and Manufacturers of America PhRMA and Questcor Pharmaceuticals, Inc., and has been a member of the Corporate Council of NORD for several years. He previously served in varying roles for SigmaTau Pharmaceuticals, Inc., a private biopharmaceutical company, from September through February , including Chief Operating Officer from November to April and Chief Executive Officer from April to February . From May, to August , he served as Vice President of Operations and Vice President, Controller of AstenJohnson, Inc. formerly JWI Inc. . Prior to that, Mr. Lapointe spent several years in the Canadian medical products industry in both distribution and manufacturing. Mr. Lapointe began his career at Price Waterhouse. Mr. Lapointe received his B.A. degree in Commerce from Concordia University in Montreal, Canada, a graduate diploma in Accountancy from McGill University and his M.B.A. degree from Duke University. He is a C.P.A. in the state of Illinois. Mr. Lapointe was selected to serve as a member of our Board of Directors because of his significant experience in the areas of global strategic planning and implementation, business development, corporate finance, and acquisitions, and his experience as an executive officer and board member in the pharmaceutical and medical products industries.
  • Robert Rubin / Director
    • Robert J. Rubin, MD has been a director since October . Dr. Rubin was a clinical professor of medicine at Georgetown University from until when he was appointed a Distinguished Professor of Medicine. From to , he was president of the Lewin Group purchased by Quintiles Transnational Corp. in , an international health policy and management consulting firm. From to , Dr. Rubin served as Medical Director of ValueRx, a pharmaceutical benefits company. From to , Dr. Rubin served as President of LewinVHI, a health care consulting company. From to , he served as President of LewinICF, a health care consulting company. From to , Dr. Rubin served as a principal of ICF, Inc., a health care consulting company. From to , Dr. Rubin served as the Assistant Secretary for Planning and Evaluation at the Department of Health and Human Services and as an Assistant Surgeon General in the United States Public Health Service. Dr. Rubin has served on the Board of BioTelemetry, Inc. formerly known as CardioNet, Inc. since . He is a board certified nephrologist and internist. Dr. Rubin received an undergraduate degree in Political Science from Williams College and his medical degree from Cornell University Medical College. Dr. Rubin was selected to serve as a member of our Board of Directors because of his vast experience in the health care industry, including his experience as a nephrologist, internist, clinical professor of medicine and Assistant Surgeon General, and his business experience in the pharmaceutical industry.
  • Jerry Zeldis / Director
    • Jerome Zeldis, MD, PhD has been a director since June . Dr. Zeldis is currently Chief Executive Officer of Celgene Global Health and Chief Medical Officer of Celgene Corporation, a publicly traded, fully integrated biopharmaceutical company, where he has been employed since . From September to February , Dr. Zeldis worked at Sandoz Research Institute and the Janssen Research Institute in both clinical research and medical development. He has been a board member of several biotechnology companies and is currently on the boards of the NJ Chapter of the Arthritis Foundation, the Castleman s Disease Organization and PTC Therapeutics, Inc. and Alliqua, Inc. Additionally, he has served as Assistant Professor of Medicine at the Harvard Medical School from July to September , Associate Professor of Medicine at University of California, Davis from September to September , Clinical Associate Professor of Medicine at Cornell Medical School January to December and Professor of Clinical Medicine at the Robert Wood Johnson Medical School July to June . Dr. Zeldis received a BA and an MS from Brown University, and an MD, and a PhD in Molecular Biophysics and Biochemistry from Yale University. Dr. Zeldis trained in Internal Medicine at the UCLA Center for the Health Sciences and in Gastroenterology at the Massachusetts General Hospital and Harvard Medical School. Dr. Zeldis was selected to serve as a member of our Board of Directors because of his experience as an executive officer of a publicly traded biopharmaceutical company and in clinical research and medical development, and his experience in the health care industry, including his experience as an internist, gastroenterologist and professor of medicine.

Current Share Structure

  • Market Cap: $17,810,506 - 03/16/2018
  • Authorized: 10,000,000 - 09/30/2016
  • Issue and Outstanding: 8,730,640 - 11/03/2017

 


Recent Filings from (OTC: SNGX)

Quarterly report with a continuing view of a company's financial position
Filing Type: 10-QFiling Source: edgar
Filing Date: May, 11 2018
Annual report with a comprehensive overview of the company
Filing Type: 10-KFiling Source: edgar
Filing Date: March, 15 2018
Amendment to the SC 13G filing
Filing Type: SC 13G/AFiling Source: edgar
Filing Date: February, 13 2018
Amendment to the SC 13G filing
Filing Type: SC 13G/AFiling Source: edgar
Filing Date: February, 13 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: January, 25 2018
Amendment to a SC 13D filing
Filing Type: SC 13D/AFiling Source: edgar
Filing Date: December, 01 2017
Prospectus filed under Rule 424(b)(3)
Filing Type: 424B3Filing Source: edgar
Filing Date: November, 30 2017
Notice from the SEC of registration effectiveness
Filing Type: EFFECTFiling Source: edgar
Filing Date: November, 30 2017
Correspondence from the Filer to the SEC
Filing Type: CORRESPFiling Source: edgar
Filing Date: November, 28 2017
Correspondence from the SEC to the Filer
Filing Type: UPLOADFiling Source: edgar
Filing Date: November, 28 2017

 

 


Daily Technical Chart for (OTC: SNGX)

Daily Technical Chart for (OTC: SNGX)


Stay tuned for daily updates and more on (OTC: SNGX)

It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

More to come on (OTC: SNGX)

Do your DD and if you choose, be ready to go!


 

The Research: All source information contained in this email is from the public sources mentioned below.

 

 
 

Thank you

DD Report
@DDReports

 

 


Disclaimer: DD Report publishes reports providing information on selected companies. DD Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. DD Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in SNGX is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. DD Report has received no compensation for the publication and circulation of this report. DD Report does not own any shares of SNGX and does not buy, sell, or trade any shares of SNGX. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by DD Report. All rights reserved. Our Full Disclaimer: https://dd.report/disclaimer/